Netherlands· NL-92f41df948b2
Ozawade 18 mg filmomhulde tabletten
A pitolisant product containing pitolisanthydrochloride, registered in Netherlands by Bioprojet Pharma. The same ATC class is registered in 15 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Pitolisant is registered in 15 of 19 countries.
Countries holding a registration under ATC N07XX11 (pitolisant), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Pitolisant · ATC N07XX11
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pitolisant costs, country by country.
Normalised to the WHO defined daily dose (18 mg), the median price runs from $21.04 in France to $43.24 in Italy — a ×2.1 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pitolisant · price per daily dose (18 mg)
USD · FX 28 Sept 2026
- IT Italy$43.24
- FR France$21.04
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- PITOLISANTHYDROCHLORIDE
- Manufacturer
- Bioprojet Pharma
- Country
- Netherlands (NL)
- ATC code
- N07XX11
- ATC class
- Pitolisant
- Defined daily dose
- 18 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/21/1546
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
272 interactions on record for pitolisant.
Graded by severity as the source publishes them — 49 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pitolisant · interactions on record
272 records
- 49 severe
- 221 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PapaverinC04AX38severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pitolisant in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaOZAWADEBioprojet Pharma, Paříž
- SwedenOzawade 18 mg Filmdragerad tablettBioprojet Pharma
- PolandOzawadeBioprojet Pharma
- BelgiumOzawade 18 mgBioprojet Pharma
- SpainOZAWADE 18 MG COMPRIMIDOS RECUBIERTOS CON PELICULABioprojet Pharma
- FinlandOzawadeBioprojet Pharma
- FranceOZAWADE 18 mg, comprimés pelliculésBIOPROJET
- IrelandOzawade 18 mg film-coated tabletsBioprojet Pharma
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ozawade, Wakix
- Liechtenstein · Ozawade, Wakix
- Norway · Ozawade, Wakix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d24170ba-9e67-4ae4-a356-de4837d8a9ac GET /v1/drugs/d24170ba-9e67-4ae4-a356-de4837d8a9ac?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ozawade-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Pitolisant",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp125933",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSPOVIDON (E 1202)",
"MACROGOL 3350",
"MAGNESIUMSTEARAAT (E 470b)",
"POLYVINYLALCOHOL (E 1203)",
"SILICIUMDIOXIDE (E 551)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"PITOLISANTHYDROCHLORIDE"
],
"leaflet_url": null,
"authorised_at": "2021/09/01",
"procedure_number": "EMEA/H/C/005117",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/21/1546",
"additional_monitoring": "N"
}See everything about pitolisant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.